Certa Therapeutics to join 40th annual J.P. Morgan Healthcare Conference virtually

Melbourne, Australia, 10 January 2022: Certa Therapeutics, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases.

The Certa Therapeutics team includingits Chief Executive Officer, Professor Darren Kelly, will be participating in the 40th annual J.P. Morgan Healthcare Conference virtually.

The conference will once again be convened in a virtual format between 10-13 January 2022 due to ongoing Covid-19 travel restrictions.

The Certa team will highlight their scientific advancements in the treatment of systemic sclerosis (SSc) and chronic kidney disease (CKD).

Certa is currently progressing its development program for its novel therapeutic platform of precision medicines for the treatment of serious inflammatory and fibrotic diseases including SSc and CKD. Certa is using genetic analysis to identify the most suitable patients for treatment.

Systemic sclerosis (SSc) is a rare autoimmune disease, causing inflammation and fibrosis (scarring/hardening) of the skin and other organs. There is a clear need for new innovative treatments as currently approved therapies are largely ineffective and can have significant side-effects.

There are currently no treatments available for kidney fibrosis, which presents in the majority of patients with CKD. Given the enormous cost of dialysis and kidney transplants to the healthcare system, finding an effective treatment for these patients remains one of the global healthcare industry’s largest unmet needs.

The annual event is one of the largest and most informative healthcare investment symposiums in the industry with more than 450 companies, both public and private, delivering presentations to more than 10,000 attendees.